Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector newsTweets 

SANOFI : PRESS RELEASE : Former Research Chemist At Global Pharmaceutical Company Sentenced To 18 Months In Prison For Theft Of Trade Secrets

share with twitter share with LinkedIn share with facebook
share via e-mail
05/07/2012 | 07:17pm CET

United States Attorney

District of New Jersey


May 7, 2012 Office of Public Affairs

www.justice.gov/usao/nj (973) 645-2888



TRENTON, N.J. - A former research chemist with global pharmaceutical company

sanofi-aventis ("sanofi") was sentenced today to 18 months in prison for stealing sanofi's trade

secrets and making them available for sale through Abby Pharmatech, Inc. ("Abby"), the U.S.

subsidiary of a Chinese chemicals company, U.S. Attorney Paul J. Fishman announced.

Yuan Li, 30, of Somerset, N.J., a Chinese national, previously pleaded guilty to an

Information charging her with one count of theft of trade secrets. Li entered her guilty plea

before U.S. District Judge Joel A. Pisano, who also imposed the sentence today in Trenton

federal court.

According to documents filed in this case and statements made in court:

Sanofi is a global healthcare company with U.S. headquarters in Bridgewater, N.J.

Among other things, sanofi is engaged in the development, manufacture and marketing of

healthcare products including the prescription drugs Allegra, Plavix, Copaxone and Ambien.

Li worked as a research scientist at sanofi's Bridgewater headquarters from October 2006

through June 2011, where she directly assisted in the development of a number of compounds

that sanofi viewed as potential building blocks for future drugs. These compounds were sanofi's

trade secrets and had not been disclosed outside of sanofi in any manner, including by means of a

patent application.

While employed at sanofi, Li was also a 50 percent partner in Abby, which is engaged in

the sale and distribution of pharmaceuticals.

Li admitted that between January 2010 and June 2011, she accessed an internal sanofi

database and downloaded information related to a number of sanofi compounds, including their

chemical structures, onto her sanofi-issued laptop computer. She also admitted she then

transferred the information to her personal home computer by sending it to her personal e-mail

address or via a USB thumb drive.

Li acknowledged that she made the stolen compounds available for sale on Abby's


In addition to the prison term, Judge Pisano sentenced Li to serve two years of supervised

release and ordered her to pay $131,000 in restitution.

U.S. Attorney Fishman credited special agents of the FBI, under the direction of Special

Agent in Charge Michael B. Ward, with the investigation.

The government is represented by Assistant U.S. Attorney Gurbir S. Grewal of the

Computer Hacking and Intellectual Property Section of the U.S. Attorney's Office Economic

Crimes Unit in Newark.

12-159 ###

Defense counsel: Paul Brickfield Esq., River Edge, N.J.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
09:01a Agenda Released for Pharmaceutical Freeze Drying 2017 Summit Featuring Pfizer..
01/19 SANOFI : and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune ..
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 NEW DENGUE HEMORRHAGIC FEVER FINDING : Insights from two large-scale phase III....
01/19 SANOFI : Findings on Dengue Hemorrhagic Fever Discussed by Investigators at Sano..
01/19 ZEALAND PHARMA AKTIESELSKABET : EU approval of Suliqua triggers USD 10 million m..
01/19 SANOFI : EU approval for Sanofi's type 2 diabetes treatment
01/19 GSK grabs Astra executive to replace pharma head
01/18 Global Influenza Market Has Been Accelerated USD 6.87 Billion in 2020
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 Pharma bigwigs acknowledge challenges with perceptions of pricing as Trump pr..
01/19 Kaleo undeterred by Mylan's trevails over EpiPen pricing; employing same cont..
01/19 Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely
01/18 Vet med industry now dominated by four firms; further mergers unlikely
01/18 New chief at Merrimack Pharma
Financials (€)
Sales 2016 36 734 M
EBIT 2016 9 202 M
Net income 2016 5 242 M
Debt 2016 6 114 M
Yield 2016 3,88%
P/E ratio 2016 16,63
P/E ratio 2017 14,88
EV / Sales 2016 2,83x
EV / Sales 2017 2,82x
Capitalization 97 703 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,1 €
Spread / Average Target 7,3%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.66%104 532
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results